Liver fibrosis affects the targeting properties of drug delivery systems to macrophage subsets in vivo
Can Ergen(University of California, Berkeley), Frank Tacke(Charité - Universitätsmedizin Berlin), Patricia M. Niemietz(Universitätsklinikum Aachen), Christian Trautwein(TUM Klinikum), Louis van Bloois(Utrecht University), Fabian Kießling(Universitätsklinikum Aachen), Felix Heymann(Universitätsklinikum Aachen), Robert Pola(Czech Academy of Sciences, Institute of Macromolecular Chemistry), Felix Gremse(RWTH Aachen University), Twan Lammers(RWTH Aachen University), Tom Luedde(Düsseldorf University Hospital), Gert Storm(Yong In University), Maike Baues(RWTH Aachen University)
Cited by 27
Related Papers
EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
|Journal of Hepatology|2024|1.6k
Senescence surveillance of pre-malignant hepatocytes limits liver cancer development
|Nature|2011|1.6k
Deep learning can predict microsatellite instability directly from histology in gastrointestinal cancer
|Nature Medicine|2019|1.5k
NF-κB in the liver—linking injury, fibrosis and hepatocellular carcinoma
|Nature Reviews Gastroenterology & Hepatology|2011|1.4k
Tumor targeting via EPR: Strategies to enhance patient responses
|Advanced Drug Delivery Reviews|2018|1.2k